Edition:
United Kingdom

AC Immune SA (ACIU.OQ)

ACIU.OQ on NASDAQ Stock Exchange Global Market

4.84USD
26 Apr 2019
Change (% chg)

$0.01 (+0.21%)
Prev Close
$4.83
Open
$4.83
Day's High
$4.85
Day's Low
$4.73
Volume
4,212
Avg. Vol
104,919
52-wk High
$17.39
52-wk Low
$3.25

Summary

Name Age Since Current Position

Martin Velasco

63 Non-Executive Independent Chairman of the Board of Directors

Andrea Pfeifer

61 2003 Chief Executive Officer

Joerg Hornstein

40 2017 Chief Financial Officer

Jean-Fabien Monin

47 2015 Chief Administrative Officer

David Lowe

2018 Interim Chief Scientific Officer

Peter Bollmann

64 2015 Non-Executive Independent Director

Thomas Graney

53 2016 Non-Executive Independent Director

Detlev Riesner

76 2004 Non-Executive Independent Director

Friedrich von Bohlen und Halbach

55 2015 Non-Executive Independent Director

Biographies

Name Description

Martin Velasco

Mr. Martin Velasco serves as Non-Executive Independent Chairman of the Board of Directors of AC Immune Ltd. He is Member of the Audit and Finance Committee and the Compensation, Nomination and Governance Committee at the Company. He has served on the Company's Board of Directors since December 2003. He is an entrepreneur and Business Angel with experience in the IT, medical and biotech areas. He serves on the board of directors or advisory board of several other high-tech companies including: as Founder, Chairman and Chief Executive Officer of Anecova, an assisted reproductive technology (ART) company and World Economic Forum Technology Pioneer 2008 as Chairman of the Supervisory Board of Cocomore, a digital communications agency and IT services firm and as a Board Member of Aridhia, a Health Informatics company. Martin is also the Founder of Infantia Foundation, a philanthropic organization aiding children in the developing world. He is an Ambassador of BlueOrchard, the leading private microfinance investment advisory company and a member of the Strategic Advisory Board of the EPFL.

Andrea Pfeifer

Prof. Dr. Andrea Pfeifer, Ph.D., has served as Chief Executive Officer of AC Immune Ltd since 2003. Prior to AC Immune she was head of Nestle's Global Research in Lausanne, Switzerland and managed a group of more than 600 people. While at Nestle, she led the scientific development of the first Functional Food, LC1, and one of the first Cosmoceutical products in a joint venture with L’Oreal, Inneov Fermete. She also co-founded the Nestle Venture Capital Fund, a Life Sciences corporate venture fund. She serves as chairwoman of the Biotechmedinvest AG Investment Fund, Basel and AB2Bio, Lausanne and is member of the Supervisory Board of Symrise AG, Holzminden. Prof. Pfeifer is a member of the CEOi Initiative on Alzheimer’s Disease. She was recognized in 2009 as Technology Pioneer by the WEF and Swiss Entrepreneur of the Year by Ernst&Young. She holds a Ph.D. in Toxicology, Cancer Research from the University of Wuerzburg, Germany and continued with post-doctoral work in Molecular Carcinogenesis at the National Institutes of Health, Human Carcinogenesis Branch, in Bethesda, USA. She is a registered Toxicologist and Pharmacist, received her habilitation from the University of Lausanne, Switzerland and is an honorary professor at the Ecole Polytechnique Federale de Lausanne, Switzerland.

Joerg Hornstein

Mr. Joerg Hornstein has been Chief Financial Officer of AC Immune Ltd since April 1, 2017. Prior to joining AC Immune, Mr. Hornstein served as Senior Vice President Group Controlling for Unternehmensgruppe Theo Mueller based in Luxembourg from January 2014 to March 2017. Between 2002 and 2013 he worked for Merck KGaA, a science and technology company in healthcare, life science and performance materials, where he held various senior finance roles. Amongst others, he was Chief Financial Officer for Merck’s operations in Indonesia and Merck Serono’s operations in China. Furthermore, he served as Vice President Group Controlling for Merck Group Headquarters in Germany and as Divisional Chief Financial Officer for Merck Millipore in the U.S. Mr. Hornstein holds an MBA with Distinction from London Business School and a Bachelor of Business Administration from Baylor University.

Jean-Fabien Monin

Mr. Jean-Fabien Monin has been Chief Administrative Officer of AC Immune Ltd since July 2015. He was Chief Financial Officer at the Company from March 2009. Prior to AC Immune, he held several positions during his tenure of 14 years at bioMerieux, an international in vitro diagnostics group, culminating in his nomination as Chief Financial Officer. His last position was Chief Financial Officer of bioMerieux Central Europe based in Vienna, Austria from December 2006 to March 2009. Mr. Monin holds a Masters in Finance and International Business from the University of Paris-Dauphine, France.

David Lowe

Dr. David A. Lowe, Ph.D., has been Interim Chief Scientific Officer at AC Immune Ltd since October 19, 2018. He was Innovation Fellow at the Company from January 2014. Previously, he was the Chief Scientific Officer at PsychoGenics Inc., Chief Scientific Officer at Memory Pharmaceuticals (acquired by Roche), Executive Vice President and Chief Scientific Officer at Fidelity Biosciences Group in Boston, president, CEO and director of Envivo Pharmaceuticals (now Forum Pharmaceuticals), Vice President and therapeutic area head at Roche Bioscience in Palo Alto, Vice President and global therapeutic area head at Bayer AG, and head of CNS Biology and deputy head of CNS Research at Sandoz Ltd (now Novartis). Dr. Lowe received his Ph.D. in Neurobiology from the University of Leeds.

Peter Bollmann

Dr. Peter Bollmann, Ph.D., has been Non-Executive Independent Director of AC Immune Ltd since December 2015. He is Chairman of the Audit and Finance Committee at the Company. He has management and finance experience in Switzerland and abroad as Chief Executive Officer, Chief Financial Officer and member of the board. His broad industry experience embraces biotechnology and medical technology firms including previous Board positions with Cytos Biotechnology and Prionics.

Thomas Graney

Mr. Thomas Graney has been Non-Executive Independent Director at AC Immune Ltd since November 15, 2016. He is Member of the Audit and Finance Committee and the Compensation, Nomination and Governance Committeeat the Company. He is the Senior Vice President and Chief Financial Officer of Vertex Pharmaceuticals, Inc. since September 2017. Prior to joining Vertex in September 2017, Mr. Graney served as the Chief Financial Officer (CFO) and Senior Vice President of Finance and Corporate Strategy at Ironwood Pharmaceuticals. At Ironwood, he was responsible for Finance, Corporate Strategy, Corporate Development, Quality, Supply Chain, IT, Corporate Communications and Investor Relations. Before Ironwood, he was with Johnson & Johnson for 20 years in various roles in the U.S. and abroad. Most recently he was the Worldwide Vice President of Finance and CFO for Ethicon Surgical Care, a medical device company. In addition, Mr. Graney has global experience that spans corporate development, commercial strategy, portfolio management and supply chain management. A Chartered Financial Analyst charterholder, Mr. Graney holds a B.S. in Accounting from the University of Delaware and an MBA in Marketing Finance and International Business from the Leonard N. Stern School of Business at New York University.

Detlev Riesner

Prof. Dr. Detlev H. Riesner, Ph.D., has been Non-Executive Independent Director of AC Immune Ltd since 2004. He is Chairman of the Compensation, Nomination and Governance Committee at the Company. He held the Chair of Biophysics at the Heinrich-Heine-University in Duesseldorf, Germany from 1980 to 2007. He has also held the positions of Dean of the Science Faculty and Vice-President of Research. From 2007 through 2017, he was a member of the university’s Board of Trustees. He worked as a research fellow at Princeton University and held a guest professorship at the department of Neurology at the University of California, San Francisco. He is a co-founder of Qiagen N.V., Netherlands, was a member and from 1999 to 2014 chairman of the Supervisory Board. He was also a member of the supervisory boards of NewLab Bioquality AG, Erkrath, Direvo AG, Köln, and Alantos AG, Heidelberg. Currently, he is the Chairman of the Advisory Board of Evoxx.

Friedrich von Bohlen und Halbach

Dr. Friedrich von Bohlen und Halbach, Ph.D., has been Non-Executive Independent Director of AC Immune Ltd since October 2015. He is co-founder and managing director of dievini Hopp BioTech holding GmbH & Co. KG. He brings industry experience from Fresenius AG, FAG Kugelfischer, and WASAG-Chemie AG, founded LION bioscience AG in 1997 (now SYGNIS Pharma AG) and served as the company’s Chief Executive Officer. He is a board member of various companies of the dievini portfolio and Chairman of Apogenix AG, CureVac AG and Novaliq GmbH. He holds a Ph.D. in Neurobiology from the Swiss Federal Institute of Technology in Zurich, Switzerland.